TY - JOUR
T1 - Breast Cancer and Atrial Fibrillation
AU - Mauro, Emanuela
AU - Lucà, Fabiana
AU - Tetta, Cecilia
AU - Parise, Orlando
AU - Parrini, Iris
AU - Parise, Gianmarco
AU - Rao, Carmelo Massimiliano
AU - Matteucci, Francesco
AU - Micali, Linda Renata
AU - Gulizia, Michele Massimo
AU - La Meir, Mark
AU - Gelsomino, Sandro
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2023 Elsevier B.V., All rights reserved.
PY - 2022/3
Y1 - 2022/3
N2 - This study aims to establish the incidence of atrial fibrillation (AF) in breast cancer (BC) patients, focusing on staging and anti-cancer treatment. A meta-analysis was conducted to investigate the incidence of AF in BC patients and compare this incidence to other cancers. Furthermore, we evaluated the occurrence of AF as an adverse effect of biological therapies vs. non-biological therapies vs. biological therapies + non-biological therapies in BC. Finally, we compared the incidence of AF in early BC and metastatic BC. Thirty studies were included. Twenty-two studies focused on BC, encompassing 166,271 patients. In the BC group, 2.7% of patients developed AF, while in the "all cancer" group, 5.8% of patients developed AF. In addition, there was no difference between different types of therapies (p = 0.61) and between early and metastatic BC (p = 0.57). The type of anti-cancer therapy and the staging of BC does not influence AF's occurrence in this neoplastic disease.
AB - This study aims to establish the incidence of atrial fibrillation (AF) in breast cancer (BC) patients, focusing on staging and anti-cancer treatment. A meta-analysis was conducted to investigate the incidence of AF in BC patients and compare this incidence to other cancers. Furthermore, we evaluated the occurrence of AF as an adverse effect of biological therapies vs. non-biological therapies vs. biological therapies + non-biological therapies in BC. Finally, we compared the incidence of AF in early BC and metastatic BC. Thirty studies were included. Twenty-two studies focused on BC, encompassing 166,271 patients. In the BC group, 2.7% of patients developed AF, while in the "all cancer" group, 5.8% of patients developed AF. In addition, there was no difference between different types of therapies (p = 0.61) and between early and metastatic BC (p = 0.57). The type of anti-cancer therapy and the staging of BC does not influence AF's occurrence in this neoplastic disease.
KW - atrial fibrillation
KW - breast cancer
KW - cancer
UR - http://www.scopus.com/inward/record.url?scp=85126000375&partnerID=8YFLogxK
U2 - 10.3390/jcm11051417
DO - 10.3390/jcm11051417
M3 - Article
C2 - 35268508
VL - 11
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
SN - 2077-0383
IS - 5
M1 - 1417
ER -